{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:09:51Z","timestamp":1777882191260,"version":"3.51.4"},"reference-count":32,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Palliat&amp;#65533;Care"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Palliative sedation is a key component of palliative care for end-stage cancer patients with refractory symptoms. In mainland China, midazolam-based titrated palliative sedation is rarely used clinically, with limited data and studies reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>To illustrate the development of clinical practice patterns for midazolam-based palliative sedation in advanced cancer patients in mainland China, identify clinical regularities, and summarize clinical experience to promote the administration of palliative sedation for terminally ill cancer patients in mainland China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A retrospective observational study was conducted using clinical records of terminal cancer patients who underwent midazolam-based palliative sedation from 2016 to 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting\/participants:<\/jats:title>\n                    <jats:p>Terminal cancer patients who underwent palliative sedation in the oncology ward of Hangzhou Hospital of Traditional Chinese Medicine, a tertiary medical center in Eastern mainland China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The overall implementation rate of palliative sedation in terminal cancer patients was 7.98% (55\/689). Refractory dyspnea was the primary indication for sedation (47.3%). The proportion of patients receiving adequate sedation was significantly higher in the titrated group than in the non-titrated group (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The mean survival time of the 50 patients who received adequate sedation was 67.45\u2009h. Among them, the mean survival time in the dyspnea subgroup (38.88\u2009h) was significantly shorter than in the pain (125.42\u2009h) and agitation (120.33\u2009h) subgroups (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The mediation analysis further demonstrated that the indication for palliative sedation (presence or absence of dyspnea) fully mediated the association between the patient\u2019s disease diagnosis (presence or absence of lung cancer) and survival time. In this study, 66.7% of family members had never previously heard of palliative sedation, and their attitudes toward this therapy were quite ambivalent.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Effective communication of palliative sedation helps improve family members\u2019 acceptance of this therapy. Patients with refractory dyspnea, especially lung cancer patients with this symptom (who may have more severe underlying disease), may have shorter survival times than those with agitation or pain. Rigorous pre-procedural risk communication with families is recommended before sedation, and close monitoring and assessment during sedation are essential for safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/26323524261436494","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:31:24Z","timestamp":1774935084000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical profile and challenges of midazolam-based palliative sedation for terminal cancer patients: A retrospective observational study from a tertiary medical center in mainland China"],"prefix":"10.1177","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5141-5377","authenticated-orcid":false,"given":"Junhua","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Oncology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazhen","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heran","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu238"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/107327481502200409"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-020-00592-3"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1478951521001371"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00482-024-00825-x"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1426257"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/02692163231220225"},{"issue":"1","key":"e_1_3_3_9_2","first-page":"62","article-title":"The use of midazolam and haloperidol in cancer patients at the end of life","volume":"53","author":"Radha Krishna LK","year":"2012","unstructured":"Radha Krishna LK, Poulose VJ, Goh C. The use of midazolam and haloperidol in cancer patients at the end of life. Singapore Med J 2012; 53(1): 62\u201366.","journal-title":"Singapore Med J"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.3.341"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1407-x"},{"key":"e_1_3_3_12_2","first-page":"1","article-title":"Midazolam: an essential palliative care drug","volume":"14","author":"Prommer E.","year":"2020","unstructured":"Prommer E. Midazolam: an essential palliative care drug. Palliat Care Soc Pract 2020; 14: 1\u201312.","journal-title":"Palliat Care Soc Pract"},{"key":"e_1_3_3_13_2","first-page":"235","article-title":"Sedation in palliative care: a clinically oriented overview of guidelines and treatment recommendations","volume":"120","author":"Klein C","year":"2023","unstructured":"Klein C, Voss R, Ostgathe C, et al. Sedation in palliative care: a clinically oriented overview of guidelines and treatment recommendations. Dtsch Arztebl Int 2023; 120: 235\u2013242.","journal-title":"Dtsch Arztebl Int"},{"key":"e_1_3_3_14_2","unstructured":"National Health Commission of Republic of China. Chinese palliative care practice guidelines 2025 Edition https:\/\/www.nhc.gov.cn\/yzygj\/c100067\/202508\/3c673651ca374d07987d37e7732995cd.shtml (2025)."},{"issue":"14","key":"e_1_3_3_15_2","first-page":"1717","article-title":"Chinese guideline for use of essential medicines in palliative and hospice care","volume":"24","author":"General Practice Branch of Cross-Strait Medicine Exchange Association","year":"2021","unstructured":"General Practice Branch of Cross-Strait Medicine Exchange Association. Chinese guideline for use of essential medicines in palliative and hospice care. Chin Gen Pract 2021; 24(14): 1717\u20131734.","journal-title":"Chin Gen Pract"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2024.0003"},{"issue":"21","key":"e_1_3_3_17_2","first-page":"31","article-title":"A survey of oncologists\u2019 attitudes towards palliative sedation for end-of-live patients","volume":"42","author":"He L-S","year":"2021","unstructured":"He L-S, Yang T, Chen J-Z, et al. A survey of oncologists\u2019 attitudes towards palliative sedation for end-of-live patients. Med Philos 2021; 42(21): 31\u201334.","journal-title":"Med Philos"},{"issue":"17","key":"e_1_3_3_18_2","first-page":"6","article-title":"The dying patient condition assessment sheet: prediction of expected survival time in advanced cancer patients","volume":"29","author":"Huang J","year":"2014","unstructured":"Huang J, Mao B. The dying patient condition assessment sheet: prediction of expected survival time in advanced cancer patients. J Nurs Sci 2014; 29(17): 6\u20138 (in Chinese).","journal-title":"J Nurs Sci"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2107138"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2020.09.022"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/spcare-2023-004669"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(98)00066-9"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2005.8.20"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-684X-2-2"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2007.10.014"},{"key":"e_1_3_3_26_2","first-page":"203","article-title":"Cancer survival statistics in China 2019\u20132021: a multicenter, population-based study","volume":"4","author":"Zeng H","year":"2024","unstructured":"Zeng H, Zheng R, Sun K, et al. Cancer survival statistics in China 2019\u20132021: a multicenter, population-based study. J Natl Cancer Cent 2024; 4: 203\u2013213.","journal-title":"J Natl Cancer Cent"},{"key":"e_1_3_3_27_2","unstructured":"The State Council of the People\u2019s Republic of China. Healthy China 2030 https:\/\/www.gov.cn\/zhengce\/2016-10\/25\/content_5124174.htm (2016)."},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0270483"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/02692163231180656"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-018-0303-7"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-016-0121-8"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyad037"},{"key":"e_1_3_3_33_2","first-page":"366","volume-title":"Oxford handbook of palliative care","author":"Watson M","year":"2014","unstructured":"Watson M, Lucas C, Hoy A, et al. Oxford handbook of palliative care. 2nd ed. Oxford: Oxford University Press, 2014, p. 366.","edition":"2"}],"container-title":["Palliative Care and Social Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/26323524261436494","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/26323524261436494","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/26323524261436494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:04:50Z","timestamp":1777597490000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/26323524261436494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":32,"alternative-id":["10.1177\/26323524261436494"],"URL":"https:\/\/doi.org\/10.1177\/26323524261436494","relation":{},"ISSN":["2632-3524","2632-3524"],"issn-type":[{"value":"2632-3524","type":"print"},{"value":"2632-3524","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"article-number":"26323524261436494"}}